SOURCE: Durrie Vision

Durrie Vision

May 09, 2016 06:00 ET

Durrie Vision Contributes to FDA Approval of Corneal Crosslinking for Treating Keratoconus

Avedro's Crosslinking System Is the First Therapeutic Keratoconus Treatment to Receive FDA Approval

OVERLAND PARK, KS--(Marketwired - May 09, 2016) - Durrie Vision, a Kansas City leader in ophthalmology and refractive surgery is thrilled to be one of the region's first to provide Avedro's Crosslinking System (KXL) for the treatment of progressive keratoconus. The announcement follows the United States Food and Drug Administration's recent approval of the KXL system, which is the first approved therapeutic treatment available for patients affected by keratoconus, a progressive disease affecting the cornea. 

The FDA approval follows results of clinical trials demonstrating stabilization of the cornea within three to twelve months after crosslinking. As one of the research study sites, Durrie Vision worked closely with the FDA and Avedro to assist in the clinical investigation of the KXL system. "After years of research and development, we are excited to see this technology receive approval and provide keratoconus patients with first-time access to a reliable solution," said Dr. Jason Stahl, Durrie Vision refractive surgeon and study investigator. Added Dr. Daniel Durrie, founder of Durrie Vision and investigator in the study, "Avedro's crosslinking system is a significant advancement for the keratoconus community, and Durrie Vision is proud to have played a role in its development."

Keratoconus is a corneal disease that occurs when the normally round shaped cornea progressively thins, causing a cone-like bulge to develop. Patients affected by the condition experience reduced visual acuity, with symptoms worsening as the disease progresses. Dr. Timothy Lindquist will be leading Durrie Vision's efforts to integrate corneal crosslinking into the practice. "Patients with keratoconus have long suffered the devastating affects of the condition. Until now their treatment options have been limited to minimizing the symptoms, but not stopping the progression of the disease. Durrie Vision is delighted to now have the technology to provide a solution to patients affected by this condition," said Dr. Lindquist.

Patients diagnosed with keratoconus can find a list of ophthalmologists familiar with corneal crosslinking here

About Durrie Vision

Durrie Vision, in Overland Park, KS, is a world-class refractive surgery center and research department located in the Kansas City metro. At Durrie Vision, our focus is providing exceptional outcomes within a world-class patient experience. Our laser vision correction options, such as advanced LASIK and refractive lens procedures, have helped thousands of people enjoy better vision. We are committed to excellence because the world turns to us for answers, and our patients turn to us for the best quality of care and technology available. Our refractive surgeons -- Dr. Daniel S. Durrie, Dr. Jason E. Stahl, and Dr. Timothy P. Lindquist -- are among the most experienced refractive surgeons in the country with international reputations and innovators and leaders in the field.

For more information about Durrie Vision, please visit Durrievision.com.

Image Available: http://www.marketwire.com/library/MwGo/2016/4/27/11G095477/Images/DV_MDs-d5bfa1cf658083189b59c1c15e8ea635.jpg

Contact Information